81,000 Vials, Rs 24 Crore In 3 Months: Weight Loss Drug Mounjaro Sales Triple As Patients Shift To Higher Dose
With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March
In a sign of rising adoption, sales of Mounjaro—the breakthrough weight loss and type 2 diabetes drug—have nearly tripled in the last two months, data shows.
American drugmaker Eli Lilly launched Mounjaro in India on March 20, triggering immediate frenzy, especially among those looking to achieve weight loss and glucose control.
Doctors told News18 they were flooded with requests from patients eager to start Mounjaro or learn more about its benefits.
With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March. The higher dosage form of five milligram, in particular, more than doubled in value and quantity sales between April and May, indicating a strong trend of patient progression to the next stage of treatment.
As per the medical protocol, patients start with lower dosage of 2.5 milligram weekly dose and upgrade to 5 milligram after four weeks.
'This clinical shift is clearly reflected in market numbers. Five mg pack sales jumped from Rs 3.08 crore in April to Rs 7.53 crore in May, while unit sales rose from over 9,300 to over 22,900," Sheetal Sapale, vice-president (commercial), Pharmatrac, told News18.
'Looking at these trends and the acceptance of this therapy—by physicians as well as patients—along with the affordable pricing of Rs 18,000 to Rs 22,000 per month dosage indicates a definite pick up in consumption."
The total market for Mounjaro has reached Rs 23.94 crore over the past three months, selling more than 81,000 vials of the drug—signalling growing adoption in diabetes care protocols.
According to Dr Anoop Misra, chairman, Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, clinical use of Mounjaro in India closely reflects the trends observed in the data.
'A substantial number of patients are being initiated at 2.5 mg, with a timely escalation to 5 mg in line with recommended protocols. This pattern suggests good tolerability and early clinical efficacy in glycemic control and weight reduction."
Misra told News18: 'With growing familiarity and broader access, increased use of higher doses (7.5 mg and above) is likely, especially in patients requiring enhanced metabolic outcomes."
The injectable drug is approved by India's apex drug regulatory body, Central Drugs Standard Control Organisation (CDSCO).
Mounjaro is a once-weekly injection priced at Rs 4,375 for a 5 mg vial and Rs 3,500 for a 2.5 mg vial, making the monthly expenditure around Rs 14,000-Rs 17,500. The drug is claimed to be 80 per cent cheaper than in the United States.
Entry-Level Dosage Sales Plateau
Mounjaro, the brand name for Tirzepatide, a once-weekly injectable, is a first-in-class medication that combines the effects of two naturally occurring hormones: GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1).
Data shows that the 2.5mg dose of Mounjaro—generally prescribed as the starting regimen for type 2 diabetes patients or those looking to shed weight—has shown signs of 'plateauing growth". This trend confirms a gradual shift to higher doses.
The sales value for the 2.5 mg injection rose marginally from Rs 4.80 crore in April to Rs 5.08 crore in May, after a steeper increase from Rs 1.42 crore in March. The data shows that the unit sales also reflect this trend, increasing from 5,400 in March to 18,270 in April, but only marginally to 19,350 in May.
While the 2.5 mg variant remains essential for entry-level patient initiation, its month-on-month growth may continue to taper off as the patient base matures and advances to the next phase of dosing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
'New lease on life': IVRI makes history with successful indigenous hip transplant for dogs in India; reduces cost to Rs 30K
BAREILLY: The scientists at the Indian Veterinary Research Institute (IVRI) achieved a milestone by successfully performing the first hip transplant surgery using indigenous technology in the country. This hip transplant is notable for being entirely developed with local technology. Until now, artificial hips for dogs were not available in India and had to be imported, costing at least Rs 5 lakhs. For nearly three years, IVRI scientists, Dr Rohit Kumar and his team, conducted a comprehensive study to develop not only a cemented hip suitable for Indian dogs but also the necessary instruments. Dr Kumar and his team took on this challenge, initially seeking insights from renowned human orthopaedic surgeon Dr Alok Singh. With technical assistance from Dr Singh and Bareilly Medicare Firm's Yogesh Saxena and Devesh Saxena, Life Ortho Care in Gujarat helped in developing the artificial hip and its instruments for dogs. Dr Rohit Kumar mentioned that the developed hip is quite affordable, allowing dog owners in the country to receive excellent treatment at a lower cost in the future. He told TOI, 'Earlier the cost of replacement surgery was very high as there was no implant manufacturer in India. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Keep Your Home Efficient with This Plug-In elecTrick - Save upto 80% on Power Bill Learn More Undo We all did a comprehensive indigenous study. Saw many surgeries in humans, developed all the dimensions on our own by taking multiple x-rays of the dogs. The cost of implant during the experimentation phase is between 25k-30k and even after commercialisation, the cost of hip replacement surgery would be very affordable. The best thing about it is that everything is developed and manufactured in India.' The technical design and dimensions were assigned to Dr T Sai Kumar for MVSc research and Dr Kamlesh Kumar for PhD research. This work was carried out under the AINP-DIMSCA (All India Network Programme on Diagnostic Imaging for Surgical Conditions in Animals) project by the team of Dr Rohit Kumar, Dr Amarpal, Dr A C Saxena, and Dr AM Pawde. Dr Amarpal said, 'This is the first time such a study was systematically conducted in the country, with the first surgery performed in Dehradun, the second in Bareilly, and the third on a police dog in Sambhal, giving them a new lease on life." On this achievement, IVRI's Director Dr Triveni Dutt lauded the collective efforts of the entire team and encouraged making this technology available to dog owners nationwide and transferring it to the industry as soon as possible.
New Indian Express
2 hours ago
- New Indian Express
Tamil Nadu health secretary directs official to oversee construction of Pentland government hospital
VELLORE: Principal Secretary of the Tamil Nadu Health and Family Welfare Department, Dr Senthilkumar, on Saturday directed officials to ensure the timely completion of construction work on the upcoming Rs 150-crore multi-specialty block at Pentland Government Hospital in Vellore by 15 June. The hospital, which is nearing completion within the existing Pentland Hospital premises, is slated for inauguration by Chief Minister M K Stalin. Final touches are being executed in preparation for the inauguration. To review progress, Dr Senthilkumar inspected the construction site, accompanied by senior officials from the health department. He examined the quality of materials, adherence to the sanctioned building plan, and pace of ongoing work. Civil works must be completed by mid-June, he instructed, following which the installation of medical equipment will begin.
Indian Express
2 hours ago
- Indian Express
PGI's multi-level parking in Chandigarh 80% ready, to start operation in July
PGIMER, Chandigarh, is all set to get a new multi-level parking facility next month, built at a cost of about Rs 50 crore. This much-awaited parking, located near the New OPD, aims to ease the growing traffic and parking problems on the campus. The PGI Standing Finance Committee had approved the project in 2015 for a second multi-level parking facility near the New OPD. However, due to multiple delays over the past 10 years, the project couldn't move forward. According to Pankaj Rai, Deputy Director, Administration, PGI, around 80% of the construction work on the multi-level parking will be completed by July, and the facility will become operational, and the remaining work is expected to be completed by November. Considering the increase in patient load and the number of vehicles, the project will provide significant relief to patients and visitors visiting PGI, saving them time. The multi-level parking will eventually have space for over 900 cars, but initially, about 550 cars can be parked by July. The new parking structure is being built over approximately 26,000 square metres of land and will have six floors and one basement. Due to delays over the years, the demand for parking has continued to increase. PGI's New OPD registers more than 10,000 patients daily, many of whom are accompanied by one or two attendants. As a result, around 20,000 vehicles now enter the PGI campus each day. Due to the shortage of parking space, people often park at the Sector 11 market, outside PGI gates, open grounds near the Advanced Cardiac Centre etc. Earlier, PGI was planning on increasing the frequency of its free shuttle service and e-rickshaws to reduce congestion in the institute's parking lots, but as per a security guard, people don't use these services. The existing and designated parking facilities and spaces at PGI are not enough, as the institute struggles with a massive crowd and traffic. PGI currently has a total of 5,505 car parking spaces, including both permanent and temporary. There are 3,753 permanent parking slots, 72 temporary slots in front of the NINE (Nursing College), 180 temporary slots behind the dental block, and 1,500 temporary slots near the swimming pool, with 3,446 parking slots for scooters and bikes. On paper, parking appears to be enough — but the ground reality is different. Every day, heavy traffic, patient vehicles, and staff cars overwhelm the system. It's common to see attendants and visitors driving around in circles looking for a free spot. The new multi-level parking is expected to ease this pressure. Since PGI cannot stop vehicles from entering, many patients are too ill to walk, the only solution lies in expanding and managing parking facilities efficiently. PGI officials say they are working on traffic control and smart parking strategies, with a one-way system for traffic introduced during peak hours.
